NCT05534919View on ClinicalTrials.gov

Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301

PHASE3CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 9, 2022

Primary Completion Date

July 17, 2024

Study Completion Date

July 17, 2024

Conditions
Primary Immunoglobulin a Nephropathy (IgAN)
Interventions
DRUG

Nefecon

Nefecon is taken orally as capsules once daily for 9 months.

Trial Locations (1)

100034

Peking University First Hospital, Beijing

All Listed Sponsors
lead

Everest Medicines (Singapore) Pte. Ltd.

OTHER